MiniMed™ 780G system demonstrates superiority over multiple daily injections with CGM for type 1 diabetes management at one-year in ADAPT study

/PRNewswire/ -- Medtronic plc (NYSE:MDT), the global leader in medical technology, today announced one-year data from the ADAPT study (n=82), the first...

Related Keywords

United States ,Ireland ,Dublin ,Berlin ,Germany ,American ,Amir Tirosh ,Ohad Cohen ,Prnewswire Medtronic ,Jennifer Mcvean ,Ryan Weispfenning ,Janet Cho ,Diabetes Technology Therapeutics ,Linkedin ,Drug Administration ,Sheba Medical Centre Israel ,Journal Of The American Medical Association ,Exchange Commission ,Senior Medical Affairs ,Medtronic ,Our Mission ,Senior Global Medical Affairs ,Lancet Diabetes ,Clinical Outcomes ,Mean Time ,Long Term Maintained Clinical Outcomes ,Senior Global Medical Affairs Director ,American Medical Association ,Senior Medical Affairs Director ,Next Frontier ,Therapy Management ,Que Dallara ,Advanced Hybrid Closed Loop ,Therapeutics February ,Diabetes Business ,Medtronic Plc ,